“Response to Singh et al., Dupilumab as a novel therapy for management of delusions of parasitosis: A case series” Authors: Dominique Fontaine, Veronica Voronina, Sarah Gonzalez, Dylan J. Parker, Larissa Pastore, Sivan Rotenberg, Brian J. Rosen, M. Shane Chapman Published: 2026 To the Editor: We read with great interest the case series by Singh et al,1 “Dupilumab as a novel therapy for management of delusions of parasitosis: A case series,” reporting partial or limited symptomatic improvement in 9 of 11 patients with delusions of parasitosis (DOP) treated with dupilumab. The authors highlight an important off-label option for a condition notoriously refractory to standard treatment.2 We report 5 additional patients treated with dupilumab for DOP in our dermatology-psychiatry-psychology multidisciplinary clinic. Five patients (aged 38, 50, 66, 69, and 71 years; 3 men and 2 women) were retrospectively reviewed (Table I). All met clinical criteria for DOP per joint assessment, and delusional belief was identified as the underlying driver of dermatologic symptoms. Four of 5 patients underwent skin biopsy, none of which demonstrated evidence of infestation. Primary DOP was diagnosed in 4 patients, in whom the delusion arises as a standalone disorder rather than secondary to another condition.3 Concurrent diagnoses of neurotic excoriations (n = 2), prurigo nodularis (n = 1), or atopic dermatitis (n = 1) in these patients reflected sequelae of delusion-driven picking rather than independent dermatoses. One patient had a pre-existing DOP diagnosis and had failed multiple prior antipsychotic trials. Patient 4 had developed DOP in the setting of severe, poorly controlled, biopsy-confirmed atopic dermatitis. No patients received concurrent antipsychotic therapy during dupilumab treatment. A standard regimen was used in all cases (600 mg loading dose, then 300 mg every 2 weeks), with adjustments noted in Table I. One patient required dose-frequency escalation after an initial plateau; another experienced recurrence after a brief insurance-related interruption, with improvement upon treatment resumption. Within 3 to 12 months, 3 patients demonstrated a partial response and 2 a complete response. One patient self-discontinued therapy after sustained clearance. No adverse events were observed.Table ISummary of patient characteristics, treatment course, and responsePatientAge (y)SexPrior therapies (failed)Dupilumab regimenFollow-upResponse150MTopical mupirocin, triamcinolone, ketoconazole, and desonide; oral doxycycline; gabapentin; N-acetylcysteine (intolerant)600 mg loading dose, followed by 300 mg every 2 wk8 moPartial271MTopical clindamycin, triamcinolone, and ketoconazole shampoo; oral doxycycline; N-acetylcysteine600 mg loading dose, followed by 300 mg every 2 wk24 mo∗Complete338FAzelaic acid; oral cefalexin; topical betamethasone and pimecrolimus; N-acetylcysteine600 mg loading dose, followed by 300 mg every 2 wk; escalated to every week after plateau6 mo (lost to follow-up)Partial466MTopical betamethasone, triamcinolone, clobetasol, and tacrolimus; oral hydroxyzine and prednisone (transient response, unsustainable); NB-UV-B (transient response and cost-prohibitive)600 mg loading dose, followed by 300 mg every 2 wk; reinitiated after brief interruptionOngoing†Complete569FTopical triamcinolone, clindamycin, ivermectin, and azelaic acid; oral doxycycline, gabapentin, and ivermectin; quetiapine, aripiprazole, and risperidone; artemisinin; NB-UV-B600 mg loading dose, followed by 300 mg every 2 wk; concurrent doxycycline 50 mg daily3 moPartialF, Female; M, male; NB-UVB, narrow-band UV-B.∗Patient 2 self-discontinued therapy after 24 months due to satisfaction with clinical resolution/clearance.†Patient 4 remains on dupilumab with continued routine follow-up. Table ISummary of patient characteristics, treatment course, and responsePatientAge (y)SexPrior therapies (failed)Dupilumab regimenFollow-upResponse150MTopical mupirocin, triamcinolone, ketoconazole, and desonide; oral doxycycline; gabapentin; N-acetylcysteine (intolerant)600 mg loading dose, followed by 300 mg every 2 wk8 moPartial271MTopical clindamycin, triamcinolone, and ketoconazole shampoo; oral doxycycline; N-acetylcysteine600 mg loading dose, followed by 300 mg every 2 wk24 mo∗Complete338FAzelaic acid; oral cefalexin; topical betamethasone and pimecrolimus; N-acetylcysteine600 mg loading dose, followed by 300 mg every 2 wk; escalated to every week after plateau6 mo (lost to follow-up)Partial466MTopical betamethasone, triamcinolone, clobetasol, and tacrolimus; oral hydroxyzine and prednisone (transient response, unsustainable); NB-UV-B (transient response and cost-prohibitive)600 mg loading dose, followed by 300 mg every 2 wk; reinitiated after brief interruptionOngoing†Complete569FTopical triamcinolone, clindamycin, ivermectin, and azelaic acid; oral doxycycline, gabapentin, and ivermectin; quetiapine, aripiprazole, and risperidone; artemisinin; NB-UV-B600 mg loading dose, followed by 300 mg every 2 wk; concurrent doxycycline 50 mg daily3 moPartialF, Female; M, male; NB-UVB, narrow-band UV-B.∗Patient 2 self-discontinued therapy after 24 months due to satisfaction with clinical resolution/clearance.†Patient 4 remains on dupilumab with continued routine follow-up. Summary of patient characteristics, treatment course, and response F, Female; M, male; NB-UVB, narrow-band UV-B. Patient 2 self-discontinued therapy after 24 months due to satisfaction with clinical resolution/clearance. Patient 4 remains on dupilumab with continued routine follow-up. Response to dupilumab was impressive: all 5 patients experienced either partial or complete response. Response in patients with primary DOP (patients 1-3 and 5) suggests dupilumab may attenuate cutaneous sensations primarily through neuronal interleukin 4 receptor α signaling in sensory neurons rather than solely via resolution of skin inflammation, although the 2 may be interconnected.3,4 A recent case of complete resolution of recalcitrant delusional infestation, following treatment with dupilumab, in a patient without dermatologic findings further supports this possibility.5 Uncontrolled atopic dermatitis may have been a confounder in patient 4. Here, dupilumab may have concurrently targeted both the underlying cutaneous disease and the associated delusional symptomatology. Notably, this patient reported that dupilumab kept “the bugs… away.” Whether this reflects resolution of cutaneous sensation-driven delusional belief, the underlying inflammatory disease process, or both cannot be distinguished. Concurrent doxycycline use by patient 5 precludes attribution of improvement to dupilumab alone, although her response following years of antipsychotic and antimicrobial failure is notable. Our case series is limited by small sample size, retrospective design, single-center setting, and lack of a control group. Prospective, multicenter studies are needed to confirm dupilumab’s role across DOP-spectrum presentations, although the authors acknowledge the associated practical challenges. Given the refractory nature of this condition, reporting cases of even partial treatment success remains vital. Conflicts of interest None disclosed.